Dr Peter M Mbelele, MD, MMED & PhD fellow - Kibong'oto Infectious Diseases Hospital, Siha Kilimanjaro, Tanzania - Medical Specialist of Microbiology/Immunology and Laboratory Medicine Physician

Dr Peter M Mbelele

MD, MMED & PhD fellow

Kibong'oto Infectious Diseases Hospital, Siha Kilimanjaro, Tanzania

Medical Specialist of Microbiology/Immunology and Laboratory Medicine Physician

Siha, Kilimanjaro | Tanzania, United Republic of

Additional Specialties: Clinical Microbiology and Infectious Diseases

ORCID logohttps://orcid.org/0000-0002-2693-187X

Dr Peter M Mbelele, MD, MMED & PhD fellow - Kibong'oto Infectious Diseases Hospital, Siha Kilimanjaro, Tanzania - Medical Specialist of Microbiology/Immunology and Laboratory Medicine Physician

Dr Peter M Mbelele

MD, MMED & PhD fellow

Introduction

Dr Peter Mbelele is a Clinical Microbiologist and Laboratory Medicine Physician, who works with Kibong'oto Infectious Diseases Hospital (KIDH) in Tanzania. Peter has vast experience in Clinical Management of Infectious Diseases such as Tuberculosis (TB) both drug susceptible and resistant TB, HIV/AIDS, and associated non-communicable diseases like diabetes, pneumoconiosis/silicosis among others. His research interest is TB research and he is currently researching on Molecular TB diagnostics for optimising clinical management of TB. His current project is looking whether Mycobacterium tuberculosis ribosomal RNA (detection of 16S rRNA by RT-qPCR, a molecular bacterial load assay) can be used to monitor treatment response in patients treated for Multidrug resistant TB in Tanzania. He is also now being involved in multi-country, mult-centre clinical trials whose potential outcome is not only to shorten treatment durations but also having similar drugs/medicines for all forms of TB.

Primary Affiliation: Kibong'oto Infectious Diseases Hospital, Siha Kilimanjaro, Tanzania - Siha, Kilimanjaro , Tanzania, United Republic of

Additional Specialties:

Research Interests:


View Dr Peter M Mbelele’s Resume / CV

Education

Mar 2017
Nelson-Mandela African Institution of Science and Technology (NM-AIST)
PhD in Life Sciences
On going up to 2020
Sep 2013 - Dec 2016
Muhimbili University of Health and Allied Sciences
Master of Medicine (MMED) in Microbiology and Immunolog
Microbiology and Immunology
Dec 2010
Muhimbili University of Health and Allied Sciences
Doctor of Medicine (M.D)

Experience

Sep 2018
Sub-investigator
SimpliciTB (B-Pa-M-Z) clinical trial
Oct 2016
Afrique One ASPIRE PhD fellow
Principle Investigator- Molecular TB diagnostics research
PhD fellowship award
Dec 2011 - Sep 2016
Clinical Microbiologist and Laboratory Medicine Physcian
Clinical Management of Infectious Diseases and associated non-communicable comorbidities and TB research
Dec 2011
Medical Officer II
clinical management of infectious diseases and training health care prvideders

Publications

5Publications

123Reads

5Profile Views

2PubMed Central Citations

Blood cytokine responses to early secreted protein antigen-6/culture filtrate protein-10 tuberculosis antigens 2 months after antituberculosis treatment among patients with drug-susceptible pulmonary tuberculosis.

Int J Mycobacteriol 2019 Jan-Mar;8(1):53-59

Department of Global Health and Biomedical Sciences, School of Life Science and Bioengineering, Nelson Mandela-African Institution for Science and Technology, Arusha, Tanzania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijmy.ijmy_30_19DOI Listing
July 2019
9 Reads

Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults.

Int J Mycobacteriol 2018 Oct-Dec;7(4):299-309

Kibong'oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro; Department of Global Health and Biomedical Sciences, School of Life Science and Bioengineering, Nelson Mandela-African Institution for Science and Technology, Arusha, Tanzania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijmy.ijmy_135_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548176PMC
June 2019
10 Reads

Improved performance of Xpert MTB/RIF assay on sputum sediment samples obtained from presumptive pulmonary tuberculosis cases at Kibong'oto infectious diseases hospital in Tanzania.

BMC Infect Dis 2017 12 29;17(1):808. Epub 2017 Dec 29.

Department of Microbiology and Immunology, School of Medicine, Muhimbili University of Health and Allied Sciences, P.O BOX 65001, Dar es Salaam, Tanzania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12879-017-2931-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747009PMC
December 2017
25 Reads
2.613 Impact Factor

Risk factors associated with multidrug resistant tuberculosis among patients referred to Kibong’oto Infectious Disease Hospital in northern Tanzania

TJHR. 2016 Oct 18(4) Doi: http://dx.doi.org/10.4314/thrb.v18i4.2

Tanzania Journal of Health Research

Background: Multidrug resistant tuberculosis (MDR-TB) remains is an important public health problem in developing world. We conducted this study to determine risk factors associated with MDR-TB and drug susceptibility pattern to second line drug among MDR TB patients in Tanzania.

Methods: Unmatched case control study was conducted at Kibong’oto Infectious Diseases Hospital in Tanzania in 2014. A case was defined as any patient whose sputum yielded Mycobacterium tuberculosis that were resistance to at least rifampin (RFP) and isoniazid (INH) whereas control was defined as those sensitive to rifampin (RFP) + isoniazid (INH).  One morning sputum sample was collected from each study subject and cultured on Löwenstein-Jensen (LJ) media for M. tuberculosis. Drug susceptibility testing of isolated M. tuberculosis was done for rifampicin, isoniazid, kanamycin and ofloxacin. A semi-structured questionnaire was used to collect socio-demographic and risk factors information for MDR-TB

Results: A total of 102 cases and 102 controls were enrolled. The predominant age group was 31- 40 years, of whom cases and controls accounted for 38 (37.3%) and 35 (34.3%) of the study subjects, respectively. Majority of participants (69% cases and 71% control) were males and self-employed (62.7% cases and 84.4% controls). More than half (52%) and approximately a quarter (24.5%) of cases and control had HIV infection, respectively. About two-thirds of cases (62.7%) were cigarette smokers compared to controls (42.2%). Previous history of TB treatment accounted for approximately three folds in cases (72.5%) and only 24.5% in controls. Risk factors independently associated with MDR-TB were previous history of treatment with first line anti-TB (OR= 3.3, 95% CI 1.7-6.3), smoking (OR=1.9, 95% CI 1.0-3.5), contact with TB case (OR=2.7, 95% CI 1.4-5.1) and history of TB. All MDR TB isolates were sensitive to kanamycin and ofloxacin.

Conclusion: MDR-TB among patients referred to Kibong’oto Infectious Diseases Hospital is associated with previous history of TB contact, smoking habit, and contact with TB case. All MDR TB isolates were sensitive to the tested second line drugs, Kanamycin and Ofloxacin.https://www.ajol.info/index.php/thrb/article/view/145793. Doi: http://dx.doi.org/10.4314/thrb.v18i4.2

View Article
September 2016

2 Citations

5 Reads

Top co-authors

Stellah G Mpagama
Stellah G Mpagama

Kibong'oto National Tuberculosis Hospital

3
Scott K Heysell
Scott K Heysell

University of Virginia

2
Sagal Y Mohamed
Sagal Y Mohamed

University of Virginia

1
Emmanuel A Mpolya
Emmanuel A Mpolya

The Graduate University for Advanced Studies (Sokendai)

1
Sayoki G Mfinanga
Sayoki G Mfinanga

University of Bergen

1
Mecky I Matee
Mecky I Matee

Muhimbili University of Health and Allied Sciences

1
Said Aboud
Said Aboud

Muhimbili University of Health and Allied Sciences

1
Kennedy K Addo
Kennedy K Addo

Noguchi Memorial Institute for Medical Research

1